Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature.
Mitani S, Kadowaki S, Komori A, Sugiyama K, Narita Y, Taniguchi H, Ura T, Ando M, Sato Y, Yamaura H, Inaba Y, Ishihara M, Tanaka T, Tajika M, Muro K. Mitani S, et al. Among authors: komori a. Medicine (Baltimore). 2017 Jun;96(22):e6874. doi: 10.1097/MD.0000000000006874. Medicine (Baltimore). 2017. PMID: 28562536 Free PMC article. Review.
CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.
Narita Y, Taniguchi H, Komori A, Nitta S, Yamaguchi K, Kondo C, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K. Narita Y, et al. Among authors: komori a. Cancer Chemother Pharmacol. 2014 Feb;73(2):409-16. doi: 10.1007/s00280-013-2367-7. Epub 2013 Dec 10. Cancer Chemother Pharmacol. 2014. PMID: 24322376
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Nomura M, Oze I, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Kawai R, Uemura N, Ishihara M, Tanaka T, Tajika M, Niwa Y, Muro K, Muto M. Nomura M, et al. Among authors: komori a. Cancer Chemother Pharmacol. 2015 Aug;76(2):357-63. doi: 10.1007/s00280-015-2806-8. Epub 2015 Jun 20. Cancer Chemother Pharmacol. 2015. PMID: 26092324
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Yamaguchi K, Taniguchi H, Komori A, Narita Y, Nitta S, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K, Mori K, Igarashi Y. Yamaguchi K, et al. Among authors: komori a. BMC Cancer. 2015 Aug 27;15:601. doi: 10.1186/s12885-015-1606-1. BMC Cancer. 2015. PMID: 26311588 Free PMC article. Clinical Trial.
A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
Taniguchi H, Komori A, Narita Y, Kadowaki S, Ura T, Andoh M, Yatabe Y, Komori K, Kimura K, Kinoshita T, Muro K. Taniguchi H, et al. Among authors: komori k, komori a. Jpn J Clin Oncol. 2016 Mar;46(3):228-33. doi: 10.1093/jjco/hyv193. Epub 2016 Jan 12. Jpn J Clin Oncol. 2016. PMID: 26759349
361 results